Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
328.80
+4.27 (+1.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amgen
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade
February 14, 2024
Investors interested in a steadily rising stream of passive income will find what they're looking for with these dividend payers.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
February 14, 2024
It faces both clinical and competitive barriers, but they might not matter.
Via
The Motley Fool
Drivers And Stock Pickers
February 13, 2024
As opposed to drivers who overestimate themselves, we seek to be above-average stock pickers by doing the things that most professional investors struggle with, like being courageous and patient.
Via
Talk Markets
Behind the Scenes of Amgen's Latest Options Trends
February 12, 2024
Via
Benzinga
Why the dividend investor may take a look at NASDAQ:AMGN.
February 12, 2024
Exploring AMGEN INC (NASDAQ:AMGN)'s dividend characteristics.
Via
Chartmill
Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review
February 08, 2024
The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
2 Unstoppable Stocks to Buy and Hold for 2024 and Beyond
February 08, 2024
These great businesses are persisting and thriving through challenging economic times.
Via
The Motley Fool
Investors' Focus Around Amgen's Obesity Drug Data Shadows Better Than Expected Q4 Earnings
February 07, 2024
Amgen's Q4 2023: 15% net profit growth, $8.2 billion total revenues beat expectations. Prolia leads with 12% sales jump. Analysts' reactions and price targets.
Via
Benzinga
S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday?
February 07, 2024
Wednesday is a bullish day on Wall Street, with major large-cap indices extending record highs, aided by robust corporate earnings. Despite the overall market optimism, concerns linger within segments...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Amgen Dips Despite Beating Fourth-Quarter Sales Expectations
February 06, 2024
Amgen beat sales and earnings estimates late Tuesday, helped by nine products that hit record sales.
Via
Investor's Business Daily
Earnings Scheduled For February 6, 2024
February 06, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.
Via
Benzinga
Preview: Amgen's Earnings
February 05, 2024
Via
Benzinga
Is Amgen Stock a Buy Now?
February 01, 2024
The biotech has an excellent track record, but that isn't enough to make its shares attractive.
Via
The Motley Fool
META The Next Great Dividend Growth Stock – Growth Stock – Either Or Both?
February 07, 2024
A technical analysis of Meta Platforms Inc. (aka Facebook) and its recent initiation of a dividend.
Via
Talk Markets
34% of the Dow Jones Industrial Average's Weighting Is Determined by Just 5 Stocks
February 07, 2024
Five well-known Dow Jones components account for more than a third -- over 13,100 points -- of its value.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition
February 06, 2024
Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday?
February 06, 2024
At noon trading in New York, major equity indices on Wall Street remain directionless as traders evaluate the future course of monetary policy ahead of several speeches by Federal Reserve officials in...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Amgen Options Trading: A Deep Dive into Market Sentiment
January 30, 2024
Via
Benzinga
US Stocks Brace For Another Day In The Red As Rally Loses Steam: Analyst Sees Market Pullback On This Indicator
February 06, 2024
The stock rally that propelled the S&P 500 and the Dow to record highs last week seems to have stalled, with Fed officials remaining non-committal about rate-cut plans.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
3 Fantastic Dow Stocks to Buy in February 2024
February 05, 2024
The venerable index is more representative of today's economy and these three Dow stocks to buy are brightly shining component stars.
Via
InvestorPlace
Topics
Economy
Stocks
Exposures
Economy
US Equities
NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?
February 05, 2024
The relaunch of Wegovy last year caused a mad dash by weight loss stocks to compete for market leadership in anti-obesity drugs.
Via
InvestorPlace
Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record
February 05, 2024
Amgen is looking to rival Eli Lilly and Novo Nordisk in weight-loss drugs.
Via
Investor's Business Daily
Expert Outlook: Amgen Through The Eyes Of 11 Analysts
January 29, 2024
Via
Benzinga
Is Amgen a Good Dividend Stock to Buy Right Now?
January 29, 2024
Its diverse product mix and strong fundamentals make a decent case.
Via
The Motley Fool
P/E Ratio Insights for Amgen
January 26, 2024
Via
Benzinga
Weight Loss Drug's New Entrant: Amgen To Compete With Novo Nordisk, Eli Lilly, As Investigational Weight Loss Drug Shows Encouraging Early Data
February 05, 2024
Amgen's AMG 133 data. Promising results in obesity drug trials, including significant weight loss and improved metabolic markers.
Via
Benzinga
Amgen's Planning to Take a Bite Out of Cancer. Here's What It Means for the Stock.
January 27, 2024
Its new approach to treating cancer is more than just a nibble around the edges.
Via
The Motley Fool
Should You Buy the Dogs of the Dow in 2024?
January 27, 2024
The popular dividend-investing strategy has been around for years. Is it right for you?
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
ABBV: This Top Biotech Just Went On A Buying Spree
January 25, 2024
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel).
Via
Talk Markets
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
January 25, 2024
The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.